Daly A.F., Rixhon M., Adam C., Dempegioti A., Tichomirowa M.A., Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006, 91(12):4769-4775.
Fernandez A., Karavitaki N., Wass J.A. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 2010, 72(3):377-382.
Scheithauer B.W., Laws E.R., Kovacs K., Horvath E., Randall R.V., Carney J.A. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin Diagn Pathol 1987, 4(3):205-211.
Beckers A., Aaltonen L.A., Daly A.F., Karhu A. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 2013, 34(2):239-277.
Daly A.F., Jaffrain-Rea M.L., Ciccarelli A., et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 2006, 91(9):3316-3323.
Herman V., Fagin J., Gonsky R., Kovacs K., Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990, 71(6):1427-1433.
Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol 2011, 7(5):257-266.
Vallar L., Spada A., Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987, 330(6148):566-568.
Reincke M., Sbiera S., Hayakawa A., et al. Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nat Genet 2015, 47(1):31-38.
Agarwal S.K., Ozawa A., Mateo C.M., Marx S.J. The MEN1 gene and pituitary tumours. Horm Res 2009, 71(Suppl. 2):131-138.
Chandrasekharappa S.C., Guru S.C., Manickam P., et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997, 276(5311):404-407.
Lemos M.C., Thakker R.V. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008, 29(1):22-32.
Thakker R.V. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol 2014, 386(1-2):2-15.
Thakker R.V., Newey P.J., Walls G.V., et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012, 97(9):2990-3011.
Matkar S., Thiel A., Hua X. Menin: a scaffold protein that controls gene expression and cell signaling. Trends Biochem Sci 2013, 38(8):394-402.
Agarwal S.K. Multiple endocrine neoplasia type 1. Front Horm Res 2013, 41:1-15.
Prezant T.R., Levine J., Melmed S. Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors. J Clin Endocrinol Metab 1998, 83(4):1388-1391.
Poncin J., Stevenaert A., Beckers A. Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. Eur J Endocrinol Eur Fed Endocr Soc 1999, 140(6):573-576.
Verges B., Boureille F., Goudet P., et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002, 87(2):457-465.
Goudet P., Dalac A., Le Bras M., et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'etude des Tumeurs Endocrines. J Clin Endocrinol Metab 2015, 100(4):1568-1577.
Beckers A., Betea D., Valdes Socin H., Stevenaert A. The treatment of sporadic versus MEN1-related pituitary adenomas. J Int Med 2003, 253(6):599-605.
Goudet P., Bonithon-Kopp C., Murat A., et al. Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines. Eur J Endocrinol Eur Fed Endocr Soc 2011, 165(1):97-105.
Trouillas J., Labat-Moleur F., Sturm N., et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 2008, 32(4):534-543.
Ellard S., Hattersley A.T., Brewer C.M., Vaidya B. Detection of an MEN1 gene mutation depends on clinical features and supports current referral criteria for diagnostic molecular genetic testing. Clin Endocrinol 2005, 62(2):169-175.
Calender A., Vercherat C., Chambe B., Dupasquier S., Fromaget M., Cordier M. New insights in genetic testing of Multiple Endocrine Neoplasia type 1 (MEN1). Pathologica 2003, 95(5):268-271.
Stratakis C.A., Schussheim D.H., Freedman S.M., et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2000, 85(12):4776-4780.
Cuny T., Pertuit M., Sahnoun-Fathallah M., et al. Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. Eur J Endocrinol Eur Fed Endocr Soc 2013, 168(4):533-541.
de Laat J.M., Dekkers O.M., Pieterman C.R., et al. Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 Study Group (DMSG). J Clin Endocrinol Metab 2015, 100(9):3288-3296.
Hernandez-Ramirez L.C., Gabrovska P., Denes J., et al. Landscape of familial isolated and young-onset pituitary adenomas: prospective diagnosis in AIP mutation carriers. J Clin Endocrinol Metab 2015, 100(9):E1242-E1254. jc20151869.
Lee M., Pellegata N.S. Multiple endocrine neoplasia syndromes associated with mutation of p27. J Endocrinol Invest 2013, 36(9):781-787.
Lee M., Pellegata N.S. Multiple endocrine neoplasia type 4. Front Horm Res 2013, 41:63-78.
Pellegata N.S., Quintanilla-Martinez L., Siggelkow H., et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 2006, 103(42):15558-15563.
Piotrowska K., Pellegata N.S., Rosemann M., Fritz A., Graw J., Atkinson M.J. Mapping of a novel MEN-like syndrome locus to rat chromosome 4. Mamm Genome Off J Int Mamm Genome Soc 2004, 15(2):135-141.
Marinoni I., Lee M., Mountford S., et al. Characterization of MENX-associated pituitary tumours. Neuropathol Appl Neurobiol 2013, 39(3):256-269.
Molatore S., Marinoni I., Lee M., et al. A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum Mutat 2010, 31(11):E1825-E1835.
Occhi G., Regazzo D., Trivellin G., et al. A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet 2013, 9(3):e1003350.
Pardi E., Mariotti S., Pellegata N.S., et al. Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4 (MEN4). Endocr Connect 2014.
Sambugaro S., Di Ruvo M., Ambrosio M.R., et al. Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region. Endocrine 2015, 49(1):58-64.
Lee M., Wiedemann T., Gross C., et al. Targeting PI3K/mTOR signaling displays potent antitumor efficacy against nonfunctioning pituitary adenomas. Clin Cancer Res Off J Am Assoc Cancer Res 2015, 21(14):3204-3215.
Tichomirowa M.A., Lee M., Barlier A., et al. Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocr Relat Cancer 2012, 19(3):233-241.
Stratakis C.A., Tichomirowa M.A., Boikos S., et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet 2010, 78(5):457-463.
Carney J.A. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Arch Int Med 1987, 147(3):418-419.
Correa R., Salpea P., Stratakis C.A. Carney complex: an update. Eur J Endocrinol Eur Fed Endocr Soc 2015, 173(4):M85-M97.
Espiard S., Bertherat J. Carney complex. Front Horm Res 2013, 41:50-62.
Schernthaner-Reiter M.H., Trivellin G., Stratakis C.A. MEN1, MEN4, and Carney complex: pathology and molecular genetics. Neuroendocrinology 2016, 103(1):18-31.
Bertherat J., Horvath A., Groussin L., et al. Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab 2009, 94(6):2085-2091.
Kurtkaya-Yapicier O., Scheithauer B.W., Carney J.A., et al. Pituitary adenoma in Carney complex: an immunohistochemical, ultrastructural, and immunoelectron microscopic study. Ultrastruct Pathol 2002, 26(6):345-353.
Stratakis C.A. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit (PRKAR1A) in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas" (Carney complex). Ann NY Acad Sci 2002, 968:3-21.
Matyakhina L., Pack S., Kirschner L.S., et al. Chromosome 2 (2p16) abnormalities in Carney complex tumours. J Med Genet 2003, 40(4):268-277.
Forlino A., Vetro A., Garavelli L., et al. PRKACB and Carney complex. N Engl J Med 2014, 370(11):1065-1067.
Berthon A.S., Szarek E., Stratakis C.A. PRKACA: the catalytic subunit of protein kinase A and adrenocortical tumors. Front Cell Dev Biol 2015, 3:26.
Cao Y., He M., Gao Z., et al. Activating hotspot L205R mutation in PRKACA and adrenal Cushing's syndrome. Science 2014, 344(6186):913-917.
Goh G., Scholl U.I., Healy J.M., et al. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat Genet 2014, 46(6):613-617.
Larkin S.J., Ferrau F., Karavitaki N., et al. Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas. Eur J Endocrinol Eur Fed Endocr Soc 2014, 171(6):705-710.
Sandrini F., Kirschner L.S., Bei T., et al. PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex. J Med Genet 2002, 39(12):e78.
Albright F., Butler A.M., Hampton A.O., Smith P. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. New Engl J Med 1937, 216(17):727-746.
Mc Cune D.J., Bruch H. Osteodystrophia fibrosa: report of a case in which the condition was combined with precocious puberty, pathologic pigmentation of the skin and hyperthyroidism, with a review of the literature. Am J Dis Children 1937, 54(4):806-848.
Boyce A.M., Chong W.H., Shawker T.H., et al. Characterization and management of testicular pathology in McCune-Albright syndrome. J Clin Endocrinol Metabol 2012, 97(9):E1782-E1790.
Collins M.T., Singer F.R., Eugster E. McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis 2012, 7(Suppl. 1):S4.
Akintoye S.O., Boyce A.M., Collins M.T. Dental perspectives in fibrous dysplasia and McCune-Albright syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol 2013, 116(3):e149-e155.
Vasilev V., Daly A.F., Thiry A., et al. McCune-Albright syndrome: a detailed pathological and genetic analysis of disease effects in an adult patient. J Clin Endocrinol Metabol 2014, 99(10):E2029-E2038.
Vortmeyer A.O., Glasker S., Mehta G.U., et al. Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome. J Clin Endocrinol Metabol 2012, 97(7):2404-2413.
Boyce A.M., Glover M., Kelly M.H., et al. Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excess. J Clin Endocrinol Metabol 2013, 98(1):E126-E134.
Salenave S., Boyce A.M., Collins M.T., Chanson P. Acromegaly and McCune-Albright syndrome. J Clin Endocrinol Metabol 2014, 99(6):1955-1969.
De Menis E., Prezant T.R. Isolated familial somatotropinomas: clinical features and analysis of the MEN1 gene. Pituitary 2002, 5(1):11-15.
Gadelha M.R., Prezant T.R., Une K.N., et al. Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J Clin Endocrinol Metab 1999, 84(1):249-256.
Gadelha M.R., Une K.N., Rohde K., Vaisman M., Kineman R.D., Frohman L.A. Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. J Clin Endocrinol Metab 2000, 85(2):707-714.
Verloes A., Stevenaert A., Teh B.T., Petrossians P., Beckers A. Familial acromegaly: case report and review of the literature. Pituitary 1999, 1(3-4):273-277.
Valdes Socin HG, Poncin J, Stevens, V, Stevenaert A, Beckers A. Adénomes hypophysaires familiaux isolés non liés avec la mutation somatique NEM-1: Suivi de 27 patients (Familial isolated pituitary adenomas not linked with somatic mutation of MEN-1: Follow-up of 27 patients). 18th Congress of the French Endocrine Society; 5-7th October, 2000.
Daly A.F., Beckers A. Familial isolated pituitary adenomas (FIPA) and mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocrinol Metabol Clin North Am 2015, 44(1):19-25.
Daly A.F., Vanbellinghen J.F., Khoo S.K., et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 2007, 92(5):1891-1896.
Vierimaa O., Georgitsi M., Lehtonen R., et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312(5777):1228-1230.
Trivellin G., Daly A.F., Faucz F.R., et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. New Engl J Med 2014, 371(25):2363-2374.
Rostomyan L., Daly A.F., Petrossians P., et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer 2015, 22(5):745-757.
Occhi G., Jaffrain-Rea M.L., Trivellin G., et al. The R304X mutation of the aryl hydrocarbon receptor interacting protein gene in familial isolated pituitary adenomas: mutational hot-spot or founder effect?. J Endocrinol Invest 2010, 33(11):800-805.
Williams F., Hunter S., Bradley L., et al. Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation. J Clin Endocrinol Metab 2014, 99(4):1122-1131.
Chahal H.S., Stals K., Unterlander M., et al. AIP mutation in pituitary adenomas in the 18th century and today. New Engl J Med 2011, 364(1):43-50.
Jennings J.E., Georgitsi M., Holdaway I., et al. Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene. Eur J Endocrinol Eur Fed Endocr Soc 2009, 161(5):799-804.
Salvatori R., Daly A.F., Quinones-Hinojosa A., Thiry A., Beckers A. A clinically novel AIP mutation in a patient with a very large, apparently sporadic somatotrope adenoma. Endocrinol Diabetes Metabol Case Rep 2014, 2014:140048.
Yu R., Bonert V., Saporta I., Raffel L.J., Melmed S. Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J Clin Endocrinol Metab 2006, 91(12):5126-5129.
DiGiovanni R., Serra S., Ezzat S., Asa S.L. AIP mutations are not identified in patients with sporadic pituitary adenomas. Endocr Pathol 2007, 18(2):76-78.
Buchbinder S., Bierhaus A., Zorn M., Nawroth P.P., Humpert P., Schilling T. Aryl hydrocarbon receptor interacting protein gene (AIP) mutations are rare in patients with hormone secreting or non-secreting pituitary adenomas. Exp Clin Endocrinol Diabetes 2008, 116(10):625-628.
Georgitsi M., De Menis E., Cannavo S., et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin Endocrinol 2008, 69(4):621-627.
Fajardo-Montanana C., Daly A.F., Riesgo-Suarez P., et al. AIP mutations in familial and sporadic pituitary adenomas: local experience and review of the literature. Endocrinologia y nutricion: organo de la Sociedad Espanola de Endocrinologia y Nutricion 2009, 56(7):369-377.
Daly A.F., Tichomirowa M.A., Petrossians P., et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 2010, 95(11):E373-E383.
Igreja S., Chahal H.S., King P., et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat 2010, 31(8):950-960.
Naves L.A., Jaffrain-Rea M.L., Vencio S.A., et al. Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene. Arquivos brasileiros de endocrinologia e metabologia 2010, 54(8):761-767.
Occhi G., Trivellin G., Ceccato F., et al. Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. Eur J Endocrinol Eur Fed Endocr Soc 2010, 163(3):369-376.
Pinho L.K., Vieira Neto L., Wildemberg L.E., et al. Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening. Arquivos brasileiros de endocrinologia e metabologia 2010, 54(8):698-704.
Cazabat L., Bouligand J., Chanson P. AIP mutation in pituitary adenomas. N Engl J Med 2011, 364(20):1973-1974. author reply 4-5.
Personnier C., Cazabat L., Bertherat J., et al. Clinical features and treatment of pediatric somatotropinoma: case study of an aggressive tumor due to a new AIP mutation and extensive literature review. Horm Res Paediatr 2011, 75(6):392-402.
Belar O., De La Hoz C., Perez-Nanclares G., Castano L., Gaztambide S. Spanish MENG. Novel mutations in MEN1, CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. Clin Endocrinol 2012, 76(5):719-724.
Cazabat L., Bouligand J., Salenave S., et al. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metab 2012, 97(4):E663-E670.
Korbonits M., Storr H., Kumar A.V. Familial pituitary adenomas - who should be tested for AIP mutations?. Clin Endocrinol 2012, 77(3):351-356.
Cai F., Zhang Y.D., Zhao X., et al. Screening for AIP gene mutations in a Han Chinese pituitary adenoma cohort followed by LOH analysis. Eur J Endocrinol Eur Fed Endocr Soc 2013, 169(6):867-884.
Nishizawa H., Fukuoka H., Iguchi G., Inoshita N., Yamada S., Takahashi Y. AIP mutation identified in a patient with acromegaly caused by pituitary somatotroph adenoma with neuronal choristoma. Exp Clin Endocrinol Diabetes Off J German Soc Endocrinol German Diabetes Assoc 2013, 121(5):295-299.
Oriola J., Lucas T., Halperin I., et al. Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. Eur J Endocrinol Eur Fed Endocr Soc 2013, 168(1):9-13.
Xekouki P., Mastroyiannis S.A., Avgeropoulos D., et al. Familial pituitary apoplexy as the only presentation of a novel AIP mutation. Endocr Relat Cancer 2013, 20(5):L11-L14.
Zatelli M.C., Torre M.L., Rossi R., et al. Should aip gene screening be recommended in family members of FIPA patients with R16H variant?. Pituitary 2013, 16(2):238-244.
Preda V., Korbonits M., Cudlip S., Karavitaki N., Grossman A.B. Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. Eur J Endocrinol Eur Fed Endocr Soc 2014, 171(5):659-666.
Schofl C., Honegger J., Droste M., et al. Frequency of AIP gene mutations in young patients with acromegaly: a registry-based study. J Clinl Endocrinol Metabol 2014, 99(12):E2789-E2793.
Urbani C., Russo D., Raggi F., et al. A novel germline mutation in the aryl hydrocarbon receptor-interacting protein (AIP) gene in an Italian family with gigantism. J Endocrinol Invest 2014, 37(10):949-955.
Hernandez-Ramirez L.C., Gabrovska P., Denes J., et al. Landscape of familial isolated and young-onset pituitary adenomas: prospective diagnosis in AIP mutation carriers. J Clin Endocrinol Metab 2015, 100(9):E1242-E1254.
Karaca Z., Taheri S., Tanriverdi F., Unluhizarci K., Kelestimur F. Prevalence of AIP mutations in a series of Turkish acromegalic patients: are synonymous AIP mutations relevant?. Pituitary 2015, 18(6):831-837.
Ferrau F., Romeo P.D., Puglisi S., et al. Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study. Endocrine 2016.
Barlier A., Vanbellinghen J.F., Daly A.F., et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J Clin Endocrinol Metab 2007, 92(5):1952-1955.
Leontiou C.A., Gueorguiev M., van der Spuy J., et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 2008, 93(6):2390-2401.
Tichomirowa M.A., Barlier A., Daly A.F., et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol Eur Fed Endocr Soc 2011, 165(4):509-515.
Vroonen L., Jaffrain-Rea M.L., Petrossians P., et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol Eur Fed Endocr Soc 2012, 167(5):651-662.
Villa C., Lagonigro M.S., Magri F., et al. Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation. Endocr Relat Cancer 2011, 18(3):347-356.
Rostomyan L., Daly A.F., Beckers A. Pituitary gigantism: causes and clinical characteristics. Annales d'endocrinologie 2015, 76(6):643-649.
Beckers A., Rostomyan L., Daly A.F. Overview of genetic testing in patients with pituitary adenomas. Annales d'endocrinologie 2012, 73(2):62-64.
Freda P.U., Beckers A.M., Katznelson L., et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011, 96(4):894-904.
Daly A.F., Yuan B., Fina F., et al. Somatic mosaicism underlies X-linked acrogigantism (XLAG) syndrome in sporadic male subjects. Endocr Relat Cancer 2016, 23(4):221-233.
Beckers A., Lodish M.B., Trivellin G., et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Relat Cancer 2015, 22(3):353-367.
Naves L.A., Daly A.F., Dias L.A., et al. Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome. Endocrine 2016, 51(2):236-244.
Daly A.F., Lysy P.A., Desfilles C., et al. GHRH excess and blockade in X-LAG syndrome. Endocr Relat Cancer 2016, 23(3):161-170.
Denes J., Swords F., Rattenberry E., et al. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metabol 2015, 100(3):E531-E541.
O'Toole S.M., Denes J., Robledo M., Stratakis C.A., Korbonits M. 15 years of paraganglioma: the association of pituitary adenomas and phaeochromocytomas or paragangliomas. Endocr Relat Cancer 2015, 22(4):T105-T122.
Xekouki P., Szarek E., Bullova P., et al. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. J Clin Endocrinol Metab 2015, 100(5):E710-E719.
